Answers are grounded in this paper and cite their sources.
Despite a lack of consensus for BCR treatment among guideline associations and medical societies, risk stratification of patients is essential for personalized treatment approaches, as it allows for an informed selection of therapeutic strategies and estimation of adverse events. In lower-risk disease, observation is recommended while in higher-risk disease, after failed repeat local therapy, ADT and/or clinical trial enrollment may be appropriate. Results from ongoing clinical studies of patients with BCR should provide consensus for management.
No takes yet. Share an insight, caveat, or question.
Shore et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: